New aspects of liver abnormalities as part of the systemic mast cell activation syndrome

Liver International

Volumn 29, Issue 2, 2009, Pages 181-186

  Alfter, Kirsten ^a,b   Von Kügelgen, Ivar ^b   Haenisch, Britta ^b   Frieling, Thomas ^c   Hülsdonk, Alexandra ^c   Haars, Ulrike ^c   Rolfs, Arndt ^d   Noe, Gerhard ^a   Kolck, Ulrich W ^a   Homann, Jürgen ^a   Molderings, Gerhard J ^e  

^a Evangelische Kliniken Bonn   (Germany)

^b UNIVERSITY OF BONN   (Germany)

^c Klinikum Krefeld   (Germany)

^d UNIVERSITY OF ROSTOCK   (Germany)

^e UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

Chitotriosidase; Hyperbilirubinaemia; Hypercholesterolaemia; Mast cell activation syndrome; Mast cell mediator syndrome; Systemic mastocytosis

Indexed keywords

AMINOTRANSFERASE; BILIRUBIN; CHITOTRIOSIDASE; CHOLESTEROL; MESSENGER RNA;

ADULT; AGED; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BILIRUBIN BLOOD LEVEL; CELL ACTIVATION; CELL ISOLATION; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISEASE ASSOCIATION; DOWN REGULATION; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATOMEGALY; HUMAN; HYPERCHOLESTEROLEMIA; KUPFFER CELL; LIVER DISEASE; LIVER STRUCTURE; MAJOR CLINICAL STUDY; MALE; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SYSTEMIC MAST CELL ACTIVATION SYNDROME; SYSTEMIC MASTOCYTOSIS;

ADOLESCENT; ADULT; AGED; BILIRUBIN; CHOLESTEROL; CROSS-SECTIONAL STUDIES; DNA MUTATIONAL ANALYSIS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEXOSAMINIDASES; HUMANS; HYPERCHOLESTEROLEMIA; LIVER DISEASES; MALE; MASTOCYTOSIS, SYSTEMIC; MIDDLE AGED; PROTO-ONCOGENE PROTEINS C-KIT; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSAMINASES;

EID: 58149493025     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2008.01839.x     Document Type: Article

References (28)

1. Valent P, Akin C, Escribano L, et al. Standards and standardization in mastocytosis: Consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest 2007; 37: 435-53.
2. Horan RF, Austen KF. Systemic mastocytosis: Restrospective review of a decade's clinical experience at the Brigham and women's hospital. J Invest Dermatol 1991; 96 (Suppl.): 5S-14S.
3. Castells M, Austen KF. Mastocytosis: Mediator related signs and symptoms. Int Arch Allergy Immunol 2002; 127: 147-52.
4. Rueff F, Dugas-Breit S, Bauer C, Placzek M, Przybolla B. Mastozytose -klinisches Bild und Diagnostik. Dtsch Med Wochenschr 2006; 131: 1616-21.
5. Molderings GJ, Kolck UW, Scheurlen C, Brüss M, Homann J, Von Kügelgen I. Multiple novel alterations in kit tyrosine kinase in patients with gastrointestinally pronounced systemic mast cell activation disorder. Scand J Gastroenterol 2007; 42: 1045-53.
6. Mican JM, Di Bisceglie AM, Fong TL, et al. Hepatic involvement in mastocytosis. Clinicopathologic correlations in 41 cases. Hepatology 1995; 22: 1163-70.
7. Jensen RT. Gastrointestinal abnormalities and involvement in systemic mastocytosis. Hematol/Oncol Clin North Am 2000; 14: 579-623.
8. Avila NA, Ling A, Worobec AS, Mican JM, Metcalfe DD. Systemic mastocytosis: CT and US features of abdominal manifestations. Radiology 1997; 202: 367-72.
9. Kupfer SS, Hart J, Mohanty SR. Systemic mastocytosis may mimic drug-induced hepatitis. Am J Gastroenterol 2005; 100: S244.
10. Marbello L, Anghilieri M, Nosari A, et al. Aggressive systemic mastocytosis mimicking sclerosing cholangitis. Haematologica 2004; 89: ECR35.
11. Molderings GJ, Kolck U, Scheurlen C, et al. Systemic mast cell disease with gastrointestinal symptoms -a diagnostic questionnaire. Dtsch Med Wochenschr 2006; 131: 2095-100.
12. Vom Dahl S, Harzer K, Rolfs A, et al. Hepatosplenomegalic lipidosis: what unless Gaucher? Adult cholesteryl ester storage disease (CESD) with anemia, mesenteric lipodystrophy, increased plasma chitotriosidase activity and a homozygous lysosomal acid lipase -1 exon 8 splice junction mutation. J Hepatol 1999; 31: 741-6.
13. Lohse P, Maas S, Lohse P, et al. Compound heterozygosity for a Wolman mutation is frequent among patients with cholesteryl ester storage disease. J Lipid Res 2000; 41: 23-31.
14. Galderisi CD, Corless CL, Wolford J, Harrell T, Heinrich MC, Press RD. Simultaneous JAK2 V617F and KIT D816V mutations in systemic mastocytosis. Mod Pathol 2006; 19: 225-6A.
15. Gotlib J, Cross NCR, Gilliland DG. Eosinophilic disorders: Molecular pathogenesis, new classification, and modern therapy. Best Pract Res Clin Haematol 2006; 19: 535-69.
16. Galli SJ, Kalesnikoff J, Grimbaldeston MA, Piliponsky AM, Williams CM, Tsai M. Mast cells as "tunable"effector and immunoregulatory cells: Recent advances. Annu Rev Immunol 2005; 23: 749-86.
17. Lennartsson J, Voytyuk O, Heiss E, Sundberg C, Sun J, Ronnstrand L. c-Kit signal transduction and involvement in cancer. Cancer Ther 2005; 3: 5-28.
18. De Backer G, Ambrosioni E, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J 2003; 24: 1601-10.
19. Liao W, Rudling M, Angelin B. Novel effects of histamine on lipoprotein metabolism: Suppression of hepatic low density lipoprotein receptor expression and reduction of plasma high density lipoprotein cholesterol in the rat. Endocrinology 1997; 138: 1863-70.
20. Franceschini B, Ceva-Grimaldi G, Russo C, Dioguardi N, Grizzi F. The complex functions of mast cells in chronic human liver diseases. Dig Dis Sci 2006; 51: 2248-56.
21. Malaguarnera L. Chitotriosidase: The yin and yang. Cell Mol Life Sci 2006; 63: 3018-29.
22. Malaguarnera L, Di Rosa M, Zambito AM, Dell'ombra N, Nicoletti F, Malaguarnera M. Chitotriosidase gene expression in Kupffer cells of non-alcoholic fatty liver disease patients. Gut 2006; 55: 1313-20.
23. Malaguarnera L, Di Rosa M, Zambito AM, Dell'ombra N, Di marco R, Malaguarnera M. Potential role of chitotriosidase gene in nonalcoholic fatty liver disease evolution. Am J Gastroenterol 2006; 101: 2060-9.
24. Helmby H, Grencis RK. IL-18 regulates intestinal mastocytosis and Th2 cytokine production independently of IFN-gamma during Trichinella spiralis infection. J Immunol 2002; 169: 2553-60.
25. Crivellato E, Beltrami CA, Mallardi F, Ribatti D. The mast cell: An active participant or an innocent bystander? Histol Histopathol 2004; 19: 259-70.
26. Ishizuka T, Okayama Y, Kobayashi H, Mori M. Interleukin-10 is localized to and released by human lung mast cells. Clin Exp Allergy 1999; 29: 1424-32.
27. Di Rosa M, Musumeci M, Scuto A, Musumeci S, Malaguarnera L. Effect of interferon-gamma, interleukin 10, lipopolysaccharide and tumor necrosis factor-alpha on chitotriosidase synthesis in human macrophages. Clin Chem Lab Med 2005; 43: 499-502.
28. Alfter K, Von Kügelgen I, Kolck UW, et al. Diagnostics and therapy of systemic mastocytosis. Med Welt 2007; 58: 621-31.